Premier Li Qiang Inspects Beijing's Biopharmaceutical Industry and Holds In-Depth Discussions with Entrepreneurs Including Fu Wei of CBC Group
Recently, Li Qiang, a member of the Standing Committee of the Political Bureau of the Communist Party of China Central Committee and Premier of the State Council, conducted field research on the development of the biopharmaceutical industry in Beijing. He presided over a symposium and held in-depth exchanges with heads of six enterprises, investment firms, R&D institutions, and medical organizations, including Fu Wei, CEO of Qiao Capital.
Premier Li Qiang emphasized that the biopharmaceutical industry is a strategic emerging sector, bearing on public health and national economic development. He pointed out the need to increase investment, promote original innovation and breakthroughs in core technologies, fully leverage the synergistic effect of government guidance and market mechanisms, attract global capital, talent, and innovative resources, and accelerate the generation of groundbreaking achievements. Particular emphasis should be placed on enhancing drug R&D, clinical trial, and production efficiency, optimizing resource allocation, and promoting high-level innovative drugs to provide strong impetus for the industry’s high-quality development.
Fu Wei, CEO of C-Bridge Capital, put forward two suggestions in his speech: first,Promote the "Beijing Model"— By leveraging the synergy between state-owned capital and market-oriented institutions to build industrial platforms, attract foreign investment, insurance capital, and other forms of funding, and accelerate the development of the biopharmaceutical industry; secondly,Call on national-level financial institutions to increase their allocation of industrial capital, support industrial capital with international capabilities, and help Chinese biopharmaceutical enterprises “go global” to seize strategic high ground worldwide.Among China’s many new quality productive forces, the biopharmaceutical industry is one of the most likely to establish systematic global leadership, creating a historic opportunity for professionals in the field to compete in world-class innovation.
As a leading healthcare investment platform in Asia, Qiao Capital has joined forces with state-owned capital platforms at both the municipal and district levels in Beijing to co-build an ecosystem of industrial-investment synergy. This collaboration enhances resource allocation efficiency, accelerates drug R&D and clinical translation, and promotes the clustering and internationalization of the industry, establishing a benchmark “Beijing Model” for the synergistic cooperation between state-owned capital and market-oriented industrial capital.
Kangqiao Capital is an asset management firm based in Asia that specializes in investments in the healthcare and medical industries, with total assets under management currently amounting to $10.5 billion. The firm has established a mature multi-product asset allocation framework, offering tailored, one-stop asset allocation solutions to meet the diverse investment needs of different types of investors in the healthcare sector. Its product offerings primarily include buyout funds, fixed-income credit funds, and life sciences infrastructure funds.
Founded in 2014, Kangqiao Capital is dedicated to creating sustained value by integrating global innovative technologies and talent, thereby building an ecosystem in the healthcare sector. By collaborating with top-tier entrepreneurs and scientists worldwide, and leveraging its unique “Investor-Operator” model, the firm strategically empowers leading healthcare companies to enhance access to medical services, foster innovation, and improve efficiency, addressing unmet medical needs globally. Headquartered in Singapore, the firm has a global presence spanning Shanghai, Beijing, Hong Kong, New York, Boston, San Diego, San Francisco, London, Abu Dhabi, Seoul, and Tokyo.